Boston Scientific Co. (NYSE:BSX) Shares Acquired by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc increased its holdings in Boston Scientific Co. (NYSE:BSX) by 0.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 113,917 shares of the medical equipment provider’s stock after acquiring an additional 615 shares during the quarter. Boston Scientific makes up about 0.9% of Marks Group Wealth Management Inc’s holdings, making the stock its 28th biggest position. Marks Group Wealth Management Inc’s holdings in Boston Scientific were worth $9,546,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Crestwood Advisors Group LLC raised its holdings in shares of Boston Scientific by 1.2% in the third quarter. Crestwood Advisors Group LLC now owns 66,531 shares of the medical equipment provider’s stock valued at $5,575,000 after buying an additional 810 shares during the last quarter. Pittenger & Anderson Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at about $419,000. FSM Wealth Advisors LLC raised its stake in Boston Scientific by 5.3% during the 3rd quarter. FSM Wealth Advisors LLC now owns 6,477 shares of the medical equipment provider’s stock valued at $543,000 after acquiring an additional 327 shares during the last quarter. Impax Asset Management Group plc grew its stake in shares of Boston Scientific by 17.5% in the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after purchasing an additional 815,403 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. increased its holdings in shares of Boston Scientific by 26.3% in the third quarter. Quintet Private Bank Europe S.A. now owns 23,581 shares of the medical equipment provider’s stock valued at $1,976,000 after purchasing an additional 4,914 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Raymond James lifted their target price on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a report on Wednesday, September 4th. TD Cowen increased their price target on shares of Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Evercore ISI lifted their price objective on Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Barclays increased their target price on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, August 22nd. Four analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

Boston Scientific Stock Up 1.0 %

Shares of NYSE:BSX opened at $85.54 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $125.97 billion, a P/E ratio of 70.69, a P/E/G ratio of 2.46 and a beta of 0.79. Boston Scientific Co. has a 52-week low of $50.84 and a 52-week high of $88.79. The stock’s fifty day simple moving average is $84.21 and its 200-day simple moving average is $78.68.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. The firm’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.50 EPS. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the transaction, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company’s stock, valued at $13,639,695. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 309,270 shares of company stock worth $26,196,718. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.